*ST赛隆(002898.SZ)公告，公司全资子公司湖南赛隆药业有限公司于近日获得国家药品监督管理局核准 签发的门冬氨酸镁《化学原料药上市申请批准通知书》及门冬氨酸钾《化学原料药上市申请批准通知 书》。化学原料药门冬氨酸钾、门冬氨酸镁可用于生产门冬氨酸钾注射液、门冬氨酸钾镁注射液等制 剂，为电解质补充药物。 ...

*ST赛隆（002898）(002898.SZ)公告，公司全资子公司湖南赛隆药业有限公司于近日获得国家药品监督 管理局核准签发的门冬氨酸镁《化学原料药上市申请批准通知书》及门冬氨酸钾《化学原料药上市申请 批准通知书》。化学原料药门冬氨酸钾、门冬氨酸镁可用于生产门冬氨酸钾注射液、门冬氨酸钾镁注射 液等制剂，为电解质补充药物。 ...

人民财讯11月28日电，*ST赛隆(002898)11月28日公告，全资子公司湖南赛隆药业有限公司于近日获得 国家药品监督管理局核准签发的门冬氨酸镁《化学原料药上市申请批准通知书》及门冬氨酸钾《化学原 料药上市申请批准通知书》。 转自：证券时报 ...

一品红（300723）(300723.SZ)公告，公司全资子公司广州市联瑞制药有限公司于近日收到国家药品监 督管理局核准签发的关于己酮可可碱缓释片的《药品注册证书》。己酮可可碱缓释片适应症为：周围性 血管疾病，包括间歇性跛行和静息疼痛。 ...

The CNBC app, global market news in one place. Customizable sections and personalized alerts. Stocks tracking, interactive charts and market insights, all in your hands.Stay connected, stay informed, download the CNBC app today. >> Welcome to Sportbox Europe. I'm Karen show with Carolyn Roth and these are your headlines.US markets prepare to return online after the Thanksgiving holiday, but an outage at exchange operator CME Group affects futures trading across equities, treasuries, and commodities. It's th ...

ments. The Airbus CEO Guom Fi has told CNBC that space is an important frontier for the company, adding that his goal is to create a key European player in the sector. Fi also touched on the company's plans to support joint European defense efforts.And Charlotte is joining us in the studio with more. She's the one that had those conversations in Paris. Walk us through what else he told you.>> Yeah, that conference again was interesting. It was about hearing the different industries and how they are adopting ...

Austin, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Parkinson’s Disease Treatment Market Size & Growth Outlook According to SNS Insider, the global Parkinson’s Disease Treatment Market was valued at $5.37 billion in 2023 and is projected to reach $8.75 billion by 2032, reflecting a CAGR of 5.57% during 2024 to 2032. The market is strengthened by a rising number of diagnosed cases, expanded use of advanced treatments such as deep brain stimulation and gene therapy, and ongoing improvements in healthcare infrastructure ...

Some of the compounds under discussion are investigational agents and are not approved by the FDA or any other regulatory agency worldwide as a treatment for indications under investigation. Efficacy and safety have not been established in areas under investigation. There are no guarantee that these compounds will become commercially available in indications under investigation. Daiichi Sankyo takes reasonable care to ensure the accuracy of the content of this material, but shall not be obliged to guarantee ...

Summary of Key Points from China Healthcare Conference and Tour Industry Overview - **Industry**: China Healthcare - **Focus**: Innovation, Globalization, and Recovery in Medical Technology (Medtech) Core Insights 1. **Innovation Hub**: China is establishing itself as a global innovation hub, particularly in novel modalities such as IO bispecific, ADC, and siRNA [1][2] 2. **Medtech Globalization**: Leading Chinese medical equipment companies are moving beyond simple exports to establish localized production and direct sales networks [1][3] 3. **IVD Market Recovery**: The domestic In-Vitro Diagnostics (IVD) market is showing signs of bottoming out, with hospitals incentivized to switch to cost-effective domestic solutions due to pricing pressures [1][4] 4. **CXO Sector Performance**: Strong orders in the CXO sector are sustained, with potential price recovery in domestic clinical CROs expected to improve gross margins in 2026 [1][5] Company-Specific Highlights 1. **Abbisko (2256.HK)** - Focus on clinical progress of irpagratinib and ABSK043, with a strong pipeline that remains undervalued in the market [15] - Irpagratinib's Phase 3 study for HCC is on track, and ABSK043 shows promise in combination therapies [16][17] 2. **Huadong Medicine (000963.SZ)** - Innovative drugs contributed Rmb1,675 million in sales for 9M25, up 62% YoY, with a focus on oncology and metabolic diseases [19] - Ongoing discussions for potential out-licensing of GLP-1 candidates and ADC [20] 3. **MicroPort MedBot (2252.HK)** - YTD overseas orders exceeded 70, indicating rapid commercialization in international markets [23] - Targeting cash flow breakeven in 2026, with a focus on increasing revenue from high-margin consumables [24][25] 4. **Shanghai Fosun Pharma (2196.HK)** - Optimistic about the inclusion of CAR-T therapy Yescarta in the innovative drug catalog of commercial insurance, expected to accelerate coverage [28] - Increasing R&D investment by 20% YoY, focusing on new modalities like radiopharmaceuticals [30] 5. **Henlius (2696.HK)** - HLX43 shows promising data in NSCLC, with plans for multiple registrational trials [31][33] - Developing a new platform for radiopharmaceuticals and small nucleic acids [32] 6. **Shenzhen Mindray (300760.SZ)** - Aiming to double its current 10% market share in IVD within three years, leveraging comprehensive lab solutions [37] - Global strategy focuses on localization and diversification of manufacturing [38] 7. **Tigermed (3347.HK)** - Positive revenue growth guidance for 2025, with strong orders in Phase 1/2 trials [40][42] - Expanding overseas operations, with significant growth in the US and Japan [43] 8. **United Imaging (688271.SS)** - Achieving robust growth in developed markets, with a CAGR of 50% for overseas markets expected [44][48] - Strong positioning in high-end MRI and molecular imaging sectors [47] Additional Insights - **siRNA Modality**: The siRNA field is at an inflection point, attracting significant interest from multinational corporations due to its long-dosing interval potential [2][9] - **Market Dynamics**: The domestic IVD market is experiencing a structural shift favoring domestic leaders, with hospitals seeking cost-effective solutions [4][14] - **Globalization Trends**: Chinese medtech firms are successfully executing globalization strategies, with significant growth in emerging markets [3][13] This summary encapsulates the key takeaways from the China Healthcare Conference and Tour, highlighting the industry's focus on innovation, globalization, and recovery, along with specific insights into leading companies within the sector.

Group 1 - The company, Hongri Pharmaceutical, primarily offers two types of products: traditional Chinese medicine formula granules and finished pharmaceuticals [1] - The traditional Chinese medicine formula granules require a doctor's prescription, while the finished pharmaceuticals include prescription drugs such as Xuebijing injection, Anruotai, Bopu Ning, and Bopu Ai [1]